A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin (G+C) for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treat

Administered By

Awarded By

Contributors

Start/End

  • October 7, 2019 - December 31, 2021